$14.5 Billion is the total value of FARALLON CAPITAL MANAGEMENT LLC's 122 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -148,952 | -100.0% | -0.01% | – |
| GOSS | Exit | GOSSAMER BIO INC | $0 | – | -100,000 | -100.0% | -0.01% | – |
| RNA | Exit | AVIDITY BIOSCIENCES INC | $0 | – | -50,000 | -100.0% | -0.01% | – |
| Exit | CTRIP COM INTL LTDdbcv 1.990% 7/0 | $0 | – | -3,508,000 | -100.0% | -0.03% | – | |
| RPTX | Exit | REPARE THERAPEUTICS INC | $0 | – | -150,000 | -100.0% | -0.04% | – |
| Exit | INTERCEPT PHARMACEUTICALS INnote 3.250% 7/0 | $0 | – | -6,500,000 | -100.0% | -0.04% | – | |
| AMTI | Exit | APPLIED MOLECULAR TRANS INC | $0 | – | -200,000 | -100.0% | -0.04% | – |
| AKUS | Exit | AKOUOS INC | $0 | – | -225,000 | -100.0% | -0.04% | – |
| ATTO | Exit | ATENTO S A | $0 | – | -11,212,205 | -100.0% | -0.06% | – |
| AKBA | Exit | AKEBIA THERAPEUTICS INC | $0 | – | -750,000 | -100.0% | -0.08% | – |
| CNST | Exit | CONSTELLATION PHARMCETICLS I | $0 | – | -350,000 | -100.0% | -0.08% | – |
| CRSP | Exit | CRISPR THERAPEUTICS AGnamen akt | $0 | – | -150,000 | -100.0% | -0.09% | – |
| RPRX | Exit | ROYALTY PHARMA PLC | $0 | – | -275,000 | -100.0% | -0.11% | – |
| TCDA | Exit | TRICIDA INC | $0 | – | -500,000 | -100.0% | -0.11% | – |
| PRNB | Exit | PRINCIPIA BIOPHARMA INC | $0 | – | -300,000 | -100.0% | -0.14% | – |
| Exit | INTERCEPT PHARMACEUTICALS INnote 2.000% 5/1 | $0 | – | -25,500,000 | -100.0% | -0.15% | – | |
| Exit | GOSSAMER BIO INCnote 5.000% 6/0 | $0 | – | -20,000,000 | -100.0% | -0.16% | – | |
| AMRN | Exit | AMARIN CORP PLCspons adr new | $0 | – | -3,125,000 | -100.0% | -0.17% | – |
| VCYT | Exit | VERACYTE INC | $0 | – | -850,000 | -100.0% | -0.18% | – |
| FXI | Exit | ISHARES TRput | $0 | – | -562,500 | -100.0% | -0.18% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -1,335,000 | -100.0% | -0.20% | – |
| FSCT | Exit | FORESCOUT TECHNOLOGIES INC | $0 | – | -1,305,000 | -100.0% | -0.22% | – |
| TGTX | Exit | TG THERAPEUTICS INC | $0 | – | -1,500,000 | -100.0% | -0.23% | – |
| Exit | HORIZON PHARMA INVT LTDnote 2.500% 3/1 | $0 | – | -15,047,000 | -100.0% | -0.24% | – | |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INC | $0 | – | -1,844,757 | -100.0% | -0.27% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -350,000 | -100.0% | -0.34% | – |
| CZR | Exit | CAESARS ENTMT CORP | $0 | – | -8,015,000 | -100.0% | -0.78% | – |
| QGEN | Exit | QIAGEN NV | $0 | – | -2,881,000 | -100.0% | -0.99% | – |
| WUBA | Exit | 58 COM INCspon adr rep a | $0 | – | -4,965,212 | -100.0% | -2.14% | – |
| IAC | Exit | IAC INTERACTIVECORP | $0 | – | -1,410,000 | -100.0% | -3.65% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MICROSOFT CORP | 44 | Q2 2024 | 3.7% |
| ALPHABET INC | 35 | Q2 2024 | 4.2% |
| GRIFOLS S A | 35 | Q2 2024 | 0.9% |
| SPDR S&P 500 ETF TR | 34 | Q2 2024 | 27.6% |
| VISA INC | 33 | Q2 2024 | 2.9% |
| RADIUS HEALTH INC | 33 | Q2 2022 | 1.7% |
| WABTEC CORP | 30 | Q2 2024 | 3.6% |
| EXELIXIS INC | 30 | Q2 2024 | 3.0% |
| SAVARA INC | 29 | Q2 2024 | 0.3% |
| TRANSUNION | 28 | Q2 2024 | 3.7% |
View FARALLON CAPITAL MANAGEMENT LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Marblegate Acquisition Corp. | February 01, 2024 | 150,000 | 2.6% |
| Clever Leaves Holdings Inc. | January 23, 2024 | ? | ? |
| SDCL EDGE Acquisition Corp | January 23, 2024 | ? | ? |
| Atento S.A. | March 15, 2023 | 2,230,357 | 15.4% |
| Metals Acquisition Corp | February 07, 2023 | 2,489,700 | 9.4% |
| Inflection Point Acquisition Corp. | February 06, 2023 | 1,900,000 | 5.8% |
| AMYRIS, INC. | February 24, 2022 | 1,068,904 | 0.3% |
| Swiftmerge Acquisition Corp. | February 14, 2022 | 291,060 | 1.3% |
| Caribou Biosciences, Inc. | February 11, 2022 | 2,428,150 | 4.0% |
| ENANTA PHARMACEUTICALS INC | February 11, 2022 | 287,000 | 1.4% |
View FARALLON CAPITAL MANAGEMENT LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 13F-HR/A | 2024-08-14 |
| 13F-HR | 2024-08-14 |
| 13F-HR/A | 2024-05-24 |
| 13F-HR/A | 2024-05-15 |
| 13F-HR/A | 2024-05-15 |
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
View FARALLON CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.